Evercore Wealth Management Lowers stake in Bristol-Myers Squibb Co (BMY)

Bristol-Myers Squibb Co (BMY) : Evercore Wealth Management reduced its stake in Bristol-Myers Squibb Co by 0.71% during the most recent quarter end. The investment management company now holds a total of 87,094 shares of Bristol-Myers Squibb Co which is valued at $6,514,631 after selling 619 shares in Bristol-Myers Squibb Co , the firm said in a disclosure report filed with the SEC on Aug 1, 2016.Bristol-Myers Squibb Co makes up approximately 0.28% of Evercore Wealth Management’s portfolio.

Other Hedge Funds, Including , Vnbtrust National Association sold out all of its stake in BMY during the most recent quarter. The investment firm sold 4,290 shares of BMY which is valued $328,056.Calamos Advisors boosted its stake in BMY in the latest quarter, The investment management firm added 58 additional shares and now holds a total of 156,752 shares of Bristol-Myers Squibb Co which is valued at $11,986,825. Bristol-Myers Squibb Co makes up approx 0.11% of Calamos Advisors’s portfolio.

Bristol-Myers Squibb Co opened for trading at $74.96 and hit $75.62 on the upside on Thursday, eventually ending the session at $75.32, with a gain of 0.70% or 0.52 points. The heightened volatility saw the trading volume jump to 34,74,924 shares. Company has a market cap of $125,849 M.

On the company’s financial health, Bristol-Myers Squibb Co reported $0.69 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $0.66. The company had revenue of $4881.00 million for the quarter, compared to analysts expectations of $4657.63 million. The company’s revenue was up 17.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.53 EPS.

Many Wall Street Analysts have commented on Bristol-Myers Squibb Co. Bristol-Myers Squibb Co was Initiated by Hilliard Lyons to “Neutral” on May 23, 2016.

Bristol-Myers Squibb Company (BMS) is engaged in the discovery development licensing manufacturing marketing distribution and sale of biopharmaceutical products across the world. The Company’s products are sold to wholesalers retail pharmacies hospitals government entities and the medical profession. The Company manufactures its products in the United States Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers such as doctors nurse practitioners physician assistants pharmacists technologists hospitals Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print radio television and digital advertising and promotion. In addition the Company holds rights to F001287 which is a preclinical small-molecule IDO1-inhibitor.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *